Dementia Clinical Network Lead - Oxford Academic Health Science Network
- Consultant Psychiatrist
Following an NIHR-funded case series exploring the use of repeated ketamine for resistant depression, we have now treated over 100 patients and are continuing to refine treatment protocols. I led a qualitative study of ECT, which led to the creation of a Healthtalk module of patients talking about their experience and an exploration of why experiences are so polarised.
As Coordinating Editor of the Cochrane Dementia and Cognitive Improvement Group I have led programmes on reviews of diagnostic test accuracy, and modifiable risk factors in dementia. I lead the Clinical Dementia Network of the Oxford Academic Health Science Network, which covers Thames Valley. I am currently exploring the use of telematics to help older people decide if they are still safe to drive.
Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO-AD trial).
Knapp M. et al, (2016), Int J Geriatr Psychiatry
Ketamine: stimulating antidepressant treatment?
Malhi GS. et al, (2016), BJPsych Open, 2, e5 - e9
Dementia and Physical Activity (DAPA) - an exercise intervention to improve cognition in people with mild to moderate dementia: study protocol for a randomized controlled trial.
Atherton N. et al, (2016), Trials, 17
Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analyses.
Howard R. et al, (2015), Lancet Neurol, 14, 1171 - 1181
Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults.
McCloud TL. et al, (2015), Cochrane Database Syst Rev